Efficacy and safety profile of avelumab monotherapy. (October 2021)

• Record Type: Journal Article
• Authors: Zhao, Bin; Gao, Meiling; Zhao, Hong; Zhao, Jiaxin; Shen, Xian
• Is Part Of: Critical reviews in oncology/hematology. Volume 166(2021)
• Publication Date: 2021-10
• Subjects: Avelumab -- Efficacy -- Safety -- Toxicity profile -- Immunotherapy -- Checkpoint inhibitors; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2021.103464
• Languages: English
• ISSNs: 1040-8428

Abstract

Graphical abstract: Highlights: Compared with conventional treatment, avelumab monotherapy was associated with an enhance efficacy. More PD-L1 positive patients responded to avelumab monotherapy compared to PD-L1 negative patients. The treatment-related adverse events were generally low-grade and manageable. No sign of increased toxicity due to the ADCC mechanism of action in avelumab monotherapy. Abstract: Avelumab can kill cancer cells through immune checkpoint inhibition and antibody-dependent cell-mediated cytotoxicity (ADCC). Here, we analyzed the clinical efficacy and adverse events (AEs) in 3935 cancer patients from 21 trials. Compared with conventional treatment, avelumab monotherapy was associated with more tumor responses and less AEs. The pooled objective response rate was 14.18 % (95 % CI, 10.68 %–18.08 %). More PD-L1 positive patients responded to avelumab monotherapy compared to PD-L1 negative patients. The overall incidence was 73.78 % for all-grade treatment-related AE (TRAE), 14.44 % for high-grade TRAE, 6.07 % for serious adverse event, 0.44 % for fatal adverse event, 17.86 % for all-grade immune-related AE (irAE), and 3.22 % for high-grade irAE. In summary, avelumab monotherapy presents an active anti-tumor activity, shows no sign of increased toxicity due to the ADCC. These characteristics provide rational for further application of avelumab in cancer treatment.